# Soriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
## 4 Clinical Trials  
Research in new pharmacological approaches for psoriasis has been intensely carried out during the last decade. In recent years, many breakthroughs in biological treatments and new small molecules have been developed. Furthermore, there are different drugs that are under clinical trials. From topical application to oral administration, there are cutting edge drugs that have been used to improve actual pharmacological arsenal for psoriasis. There are some new drugs in different types of administration are still in clinical trials at the date of this review but might be approved in the coming months (Table 3).  
Topical application is the main administration route for psoriasis-targeted drugs. As has been specified before, topical formulations are the backbone of the treatments for  
\begin{table}
\begin{tabular}{c c c c c} \hline
**Clinical Trial Phase** & **Drug Name** & **Administration Via** & **Targeting** & **References** \\ \hline \multirow{4}{*}{Phase 1} & BOS-475 & Topical & Bromodomain and extrateminal & [101] \\  & ABBV-157 & Oral & domain protein inhibitors & [102] \\ \cline{2-5}  & AC-92252 & Oral & RORyt inhibitor & [103] \\ \cline{2-5}  & EDP 1066 & Oral & Immunomodulators & [104] \\ \cline{2-5}  & EDP 1815 & Oral & Immunomodulator & [105] \\ \hline \multirow{4}{*}{Phase II} & ABY-035 & Parenteral & IL-17A inhibitor & [106] \\ \cline{2-5}  & ARQ-151 & Topical & PDE4 Enzyme inhibitor & [107] \\ \cline{2-5}  & BI 730357 & Oral & Nuclear receptor antagonist & [108] \\ \cline{2-5}  & EISO (SAN021) & Topical & PDE4 blocker & [109] \\ \cline{2-5}  & JTE-451 & Oral & ROR inhibitor & [110] \\ \cline{2-5}  & M1095 & Parenteral & Trivalent monomeric nanobody & \\  & & that neutralizes interleukins & & \\  & & IL-17A, IL-17F, and IL-17A/F & & \\ \cline{2-5}  & PF-06700841 & Topical & JAK1 and TYK2 inhibitor & [112] \\ \hline \multirow{4}{*}{Phase II} & PF-06826647 & Oral & TYK2 inhibitor & [113] \\ \cline{2-5}  & SHR-1314 & Parenteral & IL-17A Antagonist & [114] \\ \hline \multirow{4}{*}{Phase III} & BMS-986165 & Oral & Tyk2 inhibitor & [115] \\ \cline{2-5}  & BCD-085 & Parenteral & IL-17 inhibitor & [116] \\ \cline{2-5}  & BI695502 & Parenteral & TNF-\(\alpha\) inhibitor & [117] \\ \cline{2-5}  & CF101 & Oral & Adosine A3 receptor inhibitor & [118] \\ \cline{2-5}  & CHS-1420 & Parenteral & TNF-\(\alpha\) inhibitor & [119] \\ \cline{2-5}  & Filgotinib & Oral & JAK 1 inhibitor & [120] \\ \cline{2-5}  & Mirikizumab & Parenteral & IL-23 inhibitor & [121] \\ \cline{2-5}  & Serlopitant & Oral & Neurokinin-1 receptor antagonist & [122] \\ \cline{2-5}  & Tqinarof & Topical & AHR agonist & [123] \\ \cline{2-5}  & Tkdrakizumab & Parenteral & IL-23 inhibitor & [124] \\ \cline{2-5}  & Upadacitinib & Oral & JAK inhibitor & [125] \\ \hline \end{tabular}
\end{table}
Table 3: Cutting edge treatments for psoriasis under clinical trials.  
posoriasis, especially in moderate and mild cases. This is why there is important interest on the development of new formulations or new active drugs that could improve the performance of existing treatments. In fact, there are many drugs in topical formulations under clinical trials. Parenteral administration has led to different approaches in psoriasis. Despite the fact that the majority of biological treatments released in recent years have been formulated as subcutaneous medications, oral administration is the most explored in the current clinical trials.